Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inavolisib - Genentech

Next Previous
X
Search
Drug Profile

Inavolisib - Genentech

Alternative Names: GDC 0077; Itovebi; RG 6114; RO-7113755

Latest Information Update: 01 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Amides; Amines; Antineoplastics; Aza compounds; Benzene derivatives; Fluorinated hydrocarbons; Imidazoles; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 negative breast cancer
  • Phase III HER2 positive breast cancer
  • Phase II Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
  • Phase I/II Endometrial cancer
  • Phase I Colorectal cancer; Squamous cell cancer

Most Recent Events

  • 30 Oct 2024 Updated efficacy data from the phase-III INAVO120 trial in HER2-negative-breast-cancer released by Genentech ,
  • 15 Oct 2024 Discontinued - Phase-I for HER2-negative-breast-cancer (In volunteers) in USA (IV) (Genentech pipeline, October 2024)
  • 10 Oct 2024 Preregistration for HER2-negative-breast-cancer in Switzerland, Australia (PO) prior to October 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top